Dermata Therapeutics Inc (DRMA)vsRoyalty Pharma Plc (RPRX)
DRMA
Dermata Therapeutics Inc
$1.34
0.00%
HEALTHCARE · Cap: $5.21M
RPRX
Royalty Pharma Plc
$56.43
-2.64%
HEALTHCARE · Cap: $32.78B
Smart Verdict
WallStSmart Research — data-driven comparison
RPRX leads profitability with a 33.9% profit margin vs 0.0%. RPRX earns a higher WallStSmart Score of 65/100 (C+).
DRMA
Avoid26
out of 100
Grade: F
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DRMA.
Margin of Safety
-64.1%
Fair Value
$34.68
Current Price
$56.43
$21.75 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : DRMA
The strongest argument for DRMA centers on Price/Book.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : DRMA
The primary concerns for DRMA are Revenue Growth, EPS Growth, Market Cap.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
DRMA profiles as a value stock while RPRX is a mature play — different risk/reward profiles.
DRMA carries more volatility with a beta of 0.69 — expect wider price swings.
RPRX is growing revenue faster at 11.0% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (65/100 vs 26/100), backed by strong 33.9% margins and 11.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Dermata Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Dermata Therapeutics Inc. is a clinical-stage biotechnology company dedicated to innovating treatments for dermatological conditions, with a primary focus on its lead candidate, DMT310. Employing a proprietary delivery system, DMT310 aims to enhance the effectiveness of acne therapies and address critical unmet needs in the dermatology sector. With a strategically developed pipeline and a commitment to pioneering solutions, Dermata is poised to significantly impact the skin health landscape and improve patient outcomes. As the company progresses through its clinical trials, it holds the potential to become a transformative force in the treatment of various skin disorders.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?